In the first-line setting, ICI monotherapy does not provide longer overall survival (OS) than platinum-based chemotherapy in patients with advanced NSCLC with low (1–49%) PD-L1 expression (7–9) compared to those with high (≥ 50%) PD-L1 expression on tumor cells (4). This evidence concerns the gene CD274 and non-small cell lung carcinoma.